Patient characteristics and transplantation outcomes
| . | Patient 1 . | Patient 2 . |
|---|---|---|
| Age/sex | 39/M | 33/M |
| Diagnosis | AML | AML |
| CMV R/D | +/− | −/− |
| Donor | Unrelated | Sibling |
| Patient and donor HLA | ||
| A | 2402, 0201 | 0101, 2601 |
| B | 2705, 3901 | 0801, 3502 |
| C | 0102, 1203 | 0701, 0401 |
| DRB 1 | 0701, 1601 | 0301, 1104 |
| DQB 1 | 0201, 0502 | 0201, 0301 |
| Cell dose/kg recipient | ||
| CD34+, ×106 | 4.58 | 10.63 |
| CD3+, ×108 | 1.66 | 2.83 |
| HAART regimen | Efavirenz, abacavir, tenofovir | Efavirenz, abacavir, lamivudine |
| GVHD prophylaxis | CSP/MMF | CSP/MMF |
| Relapse (treatment) | Cytogenetic relapse, day +44 (CSP/MMF withdrawn) | None |
| GVHD (treatment) | Grade II skin/gut, day +56 (Pred/MMF/FK/B-B) BO, day +254 (Pred/Immuran/MMF/FK) | None |
| Survival | Died, day +301 | > 180 days |
| Cause of death | GVHD + BO | NA |
| HIV-related illness | None | None |
| HIV RNA (copies/mL) | ||
| Pre | < 30 | < 30 |
| Day +14 | < 30 | < 30 |
| Day +28 | < 30 | < 30 |
| Day +56 | < 30 | < 30 |
| Day +100 | < 30 | < 30 |
| Day 180 | < 50 | < 30 |
| HIV proviral DNA | ||
| Pre | Positive | Positive |
| Day +28 | Positive | Positive |
| Day +56 | Negative | Positive |
| Day +100 | Negative | Positive |
| HIV culture | ||
| Pre | Not isolated | Not isolated |
| Day +14 | Not isolated | Not isolated |
| Day +28 | Not isolated | Not isolated |
| Day +56 | Not isolated | Not isolated |
| Day +100 | Not isolated | Not isolated |
| CD4+ (cells/mL) | ||
| Pre | 262 | 287 |
| Day +14 | 63 | |
| Day +28 | 21 | |
| Day +56 | 78 | 315 |
| Day +100 | 74 | 248 |
| Day +180 | 56 | NA |
| CD8 (cells/mL) | ||
| Pre | 391 | 381 |
| Day +14 | 23 | |
| Day +28 | 5 | |
| Day +56 | 26 | 176 |
| Day +100 | 141 | 128 |
| Day +180 | 379 | NA |
| CD3+ % donor | ||
| Day +28 | 51% | 48% |
| Day +56 | 69% | 48% |
| Day +100 | 95% | 49% |
| Day +180 | 100% | 61% |
| CD33+ % donor | ||
| Day +28 | 94% | 100% |
| Day +56 | 99% | 100% |
| Day +100 | 100% | 100% |
| Day +180 | 100% | 100% |
| . | Patient 1 . | Patient 2 . |
|---|---|---|
| Age/sex | 39/M | 33/M |
| Diagnosis | AML | AML |
| CMV R/D | +/− | −/− |
| Donor | Unrelated | Sibling |
| Patient and donor HLA | ||
| A | 2402, 0201 | 0101, 2601 |
| B | 2705, 3901 | 0801, 3502 |
| C | 0102, 1203 | 0701, 0401 |
| DRB 1 | 0701, 1601 | 0301, 1104 |
| DQB 1 | 0201, 0502 | 0201, 0301 |
| Cell dose/kg recipient | ||
| CD34+, ×106 | 4.58 | 10.63 |
| CD3+, ×108 | 1.66 | 2.83 |
| HAART regimen | Efavirenz, abacavir, tenofovir | Efavirenz, abacavir, lamivudine |
| GVHD prophylaxis | CSP/MMF | CSP/MMF |
| Relapse (treatment) | Cytogenetic relapse, day +44 (CSP/MMF withdrawn) | None |
| GVHD (treatment) | Grade II skin/gut, day +56 (Pred/MMF/FK/B-B) BO, day +254 (Pred/Immuran/MMF/FK) | None |
| Survival | Died, day +301 | > 180 days |
| Cause of death | GVHD + BO | NA |
| HIV-related illness | None | None |
| HIV RNA (copies/mL) | ||
| Pre | < 30 | < 30 |
| Day +14 | < 30 | < 30 |
| Day +28 | < 30 | < 30 |
| Day +56 | < 30 | < 30 |
| Day +100 | < 30 | < 30 |
| Day 180 | < 50 | < 30 |
| HIV proviral DNA | ||
| Pre | Positive | Positive |
| Day +28 | Positive | Positive |
| Day +56 | Negative | Positive |
| Day +100 | Negative | Positive |
| HIV culture | ||
| Pre | Not isolated | Not isolated |
| Day +14 | Not isolated | Not isolated |
| Day +28 | Not isolated | Not isolated |
| Day +56 | Not isolated | Not isolated |
| Day +100 | Not isolated | Not isolated |
| CD4+ (cells/mL) | ||
| Pre | 262 | 287 |
| Day +14 | 63 | |
| Day +28 | 21 | |
| Day +56 | 78 | 315 |
| Day +100 | 74 | 248 |
| Day +180 | 56 | NA |
| CD8 (cells/mL) | ||
| Pre | 391 | 381 |
| Day +14 | 23 | |
| Day +28 | 5 | |
| Day +56 | 26 | 176 |
| Day +100 | 141 | 128 |
| Day +180 | 379 | NA |
| CD3+ % donor | ||
| Day +28 | 51% | 48% |
| Day +56 | 69% | 48% |
| Day +100 | 95% | 49% |
| Day +180 | 100% | 61% |
| CD33+ % donor | ||
| Day +28 | 94% | 100% |
| Day +56 | 99% | 100% |
| Day +100 | 100% | 100% |
| Day +180 | 100% | 100% |
AML indicates acute myelogenous leukemia; B-B, beclamethasone + budesnonide; BO, bronchiolitis obliterans; CMV R/D, cytomegalovirus serology of recipient/donor; CSP, cyclosporine; Dx, diagnosis; FK, FK506; GVHD, graft-versus-host disease; HIV-ID, HIV-associated; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; MSD, HLA-matched sibling donor; MUD, HLA-matched unrelated donor; NA, not applicable; and Pred, prednisone.